Literature DB >> 3889485

Captopril before and after spironolactone therapy in primary aldosteronism. Pathogenetic and therapeutical aspects.

M Stimpel, W Vetter, H Groth, P Greminger, H Vetter.   

Abstract

In three patients with primary aldosteronism, the acute effect of a single dose of captopril on the elevated mean arterial blood pressure (MAP) was studied before and after 4 weeks of treatment with spironolactone. Before spironolactone therapy, captopril did not cause any drop in MAP. Four weeks later, after an oral daily dose of 400 mg spironolactone, MAP was still elevated in all three patients, though electrolyte abnormalities were fully corrected. Since plasma renin activity (PRA) was increased to values above the normal range, the acute effect of captopril on MAP was tested again. A single dose of 25 mg captopril then caused a fall in MAP to normal. These data reveal the conversion from a renin-independent to a renin-dependent kind of hypertension after spironolactone therapy in three patients with primary aldosteronism syndrome. This might be of pathogenetic and therapeutic interest.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3889485     DOI: 10.1007/bf01731655

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Body fluid and electrolyte composition in arterial hypertension. II. Studies in mineralocorticoid hypertension.

Authors:  A V CHOBANIAN; B A BURROWS; W HOLLANDER
Journal:  J Clin Invest       Date:  1961-02       Impact factor: 14.808

2.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

3.  Sodium, extracellular fluid volume, and cardiac output changes in the genesis of mineralocorticoid hypertension in the intact dog.

Authors:  K Onoyama; E L Bravo; R C Tarazi
Journal:  Hypertension       Date:  1979 May-Jun       Impact factor: 10.190

4.  Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor.

Authors:  J H Laragh; D B Case; S A Atlas; J E Sealey
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

5.  Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism.

Authors:  J R Luderer; L M Demers; T S Harrison; A H Hayes
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

6.  Effect of prostaglandin inhibition on the hypertensive action of sodium-retaining steroids.

Authors:  K Martin; R Zipser; R Horton
Journal:  Hypertension       Date:  1981 Sep-Oct       Impact factor: 10.190

7.  The treatment of low-renin ("primary") hyperaldosteronism.

Authors:  J B Ferriss; D G Beevers; K Boddy; J J Brown; D L Davies; R Fraser; D Kremer; A F Lever; J I Robertson
Journal:  Am Heart J       Date:  1978-07       Impact factor: 4.749

8.  Combined captopril and spironolactone treatment in Conn's syndrome with renal impairment and refractory hypertension.

Authors:  A B Atkinson; J J Brown; D L Davies; A F Lever; J I Robertson
Journal:  Clin Endocrinol (Oxf)       Date:  1981-01       Impact factor: 3.478

9.  Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.

Authors:  J J Brown; D L Davies; J B Ferriss; R Fraser; E Haywood; A F Lever; J I Robertson
Journal:  Br Med J       Date:  1972-06-24

10.  Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism.

Authors:  F Mantero; F Fallo; G Opocher; D Armanini; M Boscaro; C Scaroni
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

View more
  2 in total

1.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

2.  Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.

Authors:  M Stimpel; K Ivens; H P Volkmann; G Wambach; W Kaufmann
Journal:  Klin Wochenschr       Date:  1989-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.